Product Information
CEPHALEXIN 250 MG/5 ML SUSP is a generic product labeled by Ascend Laboratories, LLC, priced at $0.0710 per ML under NDC 67877054588. Its NADAC has been published 374 times since Aug 7, 2019.
FDA first approved this application on Mar 26, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Cephalexin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/5mL
Manufacturer
Ascend Laboratories, LLCNDC
67877054588
Classification
Generic
Dosage Form
FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CEPHALEXINApproval Type
Generic (ANDA)
FDA Application
ANDA210221FDA Approved
3/26/2019
TE Code
AB
On Market Since
3/28/2019
Pharmacological Classes
Price Statistics
The NADAC for CEPHALEXIN 250 MG/5 ML SUSP has been published 374 times since Aug 7, 2019, and over the history we have for it it has declined 38.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0710 per ML |
|---|---|
| All-time high | $0.1168 (Jan 12, 2022) |
| All-time low | $0.0541 (Jul 17, 2024) |
| 52-week high | $0.0790 |
| 52-week low | $0.0710 |
| Median price | $0.0937 |
| Average price | $0.0927 |
| Largest weekly change | +66.4% (Aug 21, 2024) |
| Weeks tracked | 374 |
| Tracking since | Aug 7, 2019 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 30% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Cephalexin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEPHALEXIN 250 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for CEPHALEXIN 250 MG/5 ML SUSP, manufactured by Ascend Laboratories, LLC, is $0.0710 per ML (NDC 67877054588), effective Sep 30, 2026.
How has the price of CEPHALEXIN 250 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for CEPHALEXIN 250 MG/5 ML SUSP has declined 38.3%. It has been tracked across 374 weekly CMS publications since Aug 7, 2019.
What are the highest and lowest recorded NADAC prices for CEPHALEXIN 250 MG/5 ML SUSP?
Since Aug 7, 2019, the NADAC for CEPHALEXIN 250 MG/5 ML SUSP has ranged from a low of $0.0541 (Jul 17, 2024) to a high of $0.1168 (Jan 12, 2022), with a median of $0.0937 per ML.
Are there cheaper alternatives to CEPHALEXIN 250 MG/5 ML SUSP?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CEPHALEXIN 250 MG/5 ML SUSP, is $0.0495 per ML — about 30% below CEPHALEXIN 250 MG/5 ML SUSP.
Who manufactures CEPHALEXIN 250 MG/5 ML SUSP?
CEPHALEXIN 250 MG/5 ML SUSP (NDC 67877054588) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.